510(k) device
WavelinQ 4F EndoAVF System
C.R. Bard, Inc. · Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK, Class II) · First FDA decision Feb 6, 2019, newest Feb 6, 2019Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "WavelinQ 4F EndoAVF"
MAUDE reports
4
Brand "WavelinQ 4F EndoAVF", since 2015
PubMed studies
1
Mentioning "WavelinQ 4F EndoAVF"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing WavelinQ 4F EndoAVF System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K182796 · Decided Feb 6, 2019 · 128 days after receipt
Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "WavelinQ 4F EndoAVF", any status and sponsor, newest update first.
No registered device study names "WavelinQ 4F EndoAVF".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "WavelinQ 4F EndoAVF", and for the whole product code for context.
This brand
4 reports: 4 malfunction, 0 injury, 0 death
Whole product code PQK
492 reports: 273 malfunction, 212 injury, 7 death
Newest reports for this brand
- WAVELINQ 4F ENDOAVF SYSTEMMalfunction
9616666-2021-00026 · Received Mar 12, 2021 · Event dated Feb 18, 2021
Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK)
Device problem as coded: Failure to Cut
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1637-2020 · Started Apr 12, 2019
Reason given: The firm has become aware of a potential problem with their venous and arterial magnetic catheters may be at risk of experiencing a magnetic deficiency, which may result in the magnets failing to attract to one another. This may result in procedural delay in obtaining or creating a functional fistula and need for...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK)
Published research
The most relevant PubMed records for "WavelinQ 4F EndoAVF"[tiab]. The summary above synthesizes these.
- What is the MAUDE Database Telling us about 510(k) Authorization? Evaluation of Two Generations of Endovascular Arteriovenous Fistula Devices.
Hogan D, Otoya D, Lavingia K, et al. · Ann Vasc Surg · 2024Comparative Study
Other devices of this type
Also filed under product code PQK.
- Ellipsys Vascular Access System (Ellipsys System)Avenu Medical · De Novo 2019
- WavelinQ Plus EndoAVF SystemC.R. Bard, Inc. · 510(k) 2019
- everlinQ endoAVF SystemTva Medical, Inc. · De Novo 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.